Eton Pharmaceuticals, Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019. Financial amounts are in thousands of dollars except per-share data. The interim financial statements are unaudited.
Business context and reporting period
Eton is a development-stage specialty pharmaceutical company pursuing prescription products, primarily through the FDA’s 505(b)(2) pathway. Management said four product candidates had been submitted to the FDA and were under review. The company had limited revenue-producing operations and expected significant revenue to depend on successful development and regulatory approvals.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 |
|---|---|---|
| Revenue | $500 | $0 |
| Research and development expense | $6,465 | $1,274 |
| General and administrative expense | $1,589 | $1,690 |
| Operating loss | $(7,554) | $(2,964) |
| Net loss | $(7,410) | $(3,018) |
| Net loss per share, basic and diluted | $(0.42) | $(1.05) |
| Operating cash used | $(6,767) | $(1,850) |
| Capital expenditures | $(388) | $(91) |
Revenue was the $500 upfront payment from Bausch Health Ireland for EM-100 product rights. The agreement also provides for up to $2,500 in commercial milestones and royalties in the low-double-digit percentage range, subject to reductions under specified conditions. No royalty revenue had been recognized.
Cash and cash equivalents were $19,584 at March 31, 2019, down from $26,735 at year-end 2018. Current assets were $21,527 and current liabilities $3,656. Total liabilities were $3,775, including $242 of operating lease liabilities; the filing reports no borrowings. The accumulated deficit was $53,278. Management believed cash would fund operating expenses and capital expenditures for at least twelve months from issuance of the statements, based on current assumptions and spending management.
Gross profit and gross margin were not separately presented. Given the company’s development-stage operations, the filing focuses on operating expenses and losses rather than product margins.
Material changes versus the prior comparable period
- Revenue began in Q1 2019, while the comparable 2018 quarter had none.
- R&D expense rose by $5,191, principally reflecting increased product licensing and development activity. Q1 2019 R&D included $2,000 for ET-202 and $1,000 for ET-203 licensing payments, $1,656 for DS-200, and a $1,500 DS-200 NDA-submission milestone accrued in accounts payable.
- Net loss increased to $7,410 from $3,018, and operating cash use increased to $6,767 from $1,850. Management attributed the higher cash use mainly to greater product development and licensing activity and business expansion.
- G&A expense decreased to $1,589 from $1,690, mainly due to lower stock-based compensation, partly offset by increased personnel and public-company costs.
- Cash and cash equivalents at quarter-end were $19,584, compared with $11,215 at March 31, 2018; the company’s November 2018 IPO generated $21,960 in net proceeds.
Outlook, risks, contingencies, and unusual items
- No specific revenue or earnings guidance was provided. Management expected significant revenue to depend on product development and FDA approvals and anticipated higher G&A costs as the company grew and met public-company requirements.
- Management cautioned that cash could be used sooner than expected. Delays or inability to secure additional financing, if needed, could require the company to scale back or discontinue operations; future financing could dilute shareholders or impose debt covenants.
- Management reported that a competitor received FDA approval in April 2019 for an injectable formulation of DS-300’s active ingredient for the proposed indication. Eton believed the market could support multiple competitors.
- On May 6, 2019, after quarter-end, Eton agreed to sell CT-100 rights to Harrow for development and commercial milestone payments and low-single-digit royalties. The filing also describes related-party relationships and agreements involving Harrow and entities affiliated with Eton’s CEO.
- Eton adopted the lease accounting standard on January 1, 2019, recognizing operating lease right-of-use assets and liabilities; management said adoption did not materially affect financial condition, results, or cash flows.
- The company reported no pending or threatened litigation expected to have a material operational impact, no material changes to the risk factors in its 2018 Form 10-K, and effective disclosure controls for the quarter.
Important facts for investors to verify
- Cash runway assumptions and quarterly cash burn, particularly as licensing, development, and regulatory spending continue.
- FDA review status and timing for the four submitted candidates, and the competitive implications of the DS-300-related approval.
- Terms, milestones, royalty provisions, and related-party aspects of the Bausch/EM-100 and Harrow/CT-100 transactions.
- Unpaid and potential future licensing milestones, including the $1,500 DS-200 amount accrued at quarter-end and subsequent payment, as well as approval-contingent commitments.
- Whether product approvals and launches produce meaningful revenue, royalties, or cash receipts; the filing reported no royalty revenue to date.